Breakingviews on Twitter
Search League Tables

Saturday, 28 May 2016

Baxter’s $4 bln deal is curious deja vu

Trust us

The U.S. drugs company is buying dialysis specialist Gambro. Strategically and financially the Swedish target looks a decent fit, for instance soaking up some offshore cash. But Baxter largely exited the segment in 2005, and its record of errors ups the risk of getting back in.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.

Sign In

(Launches in a new window)